<DOC>
	<DOCNO>NCT02336243</DOCNO>
	<brief_summary>This study evaluate effectiveness maternal supplementation Docosahexaenoic acid ( DHA ) early pregnancy reduce incidence deep placentation disorder : preterm birth , preterm labor , preterm premature rupture membrane , preeclampsia fetal growth restriction . Half participant early pregnancy receive DHA 600 mg per day , half receive placebo . Investigators study also ability DHA supplementation , early pregnancy , enhance invasion transformation spiral artery trophoblast , deep placentation indicator .</brief_summary>
	<brief_title>A Randomized Trial Docosahexaenoic Acid Supplementation During Pregnancy Prevent Deep Placentation Disorders</brief_title>
	<detailed_description>Introduction : uteroplacental ischemia may cause preterm birth , either due preterm labor , preterm premature rupture membrane , medical indication ( presence preeclampsia fetal growth restriction ) . Uteroplacental ischemia product defective deep placentation , failure invasion transformation spiral artery trophoblast . It report failure normal placentation generates series clinical abnormality nowadays call `` deep placentation disorder '' ; include preeclampsia ( PE ) , fetal growth restriction ( FGR ) , preterm labor ( PL ) , preterm premature rupture membrane ( PPROM ) , utero fetal death placental abruption . Strategies prevent deep placentation disorder partially effective . Docosahexaenoic acid ( DHA ) essential fatty acid family long chain polyunsaturated fatty acid ( LC-PUFAs ) omega-3 fatty acid . Early report , suggest LC-PUFAs rich diet reduces incidence deep placentation disorder . Recent randomize control trial inconsistent show benefit DHA supplementation pregnancy prevent deep placentation disorder ; show DHA supplementation associate low risk early preterm birth . Hypothesis : investigator propose Docosahexaenoic acid ( DHA ) supplementation , early pregnancy , reduce incidence deep placentation disorder ( preterm birth , preterm labor , preterm premature rupture membrane , preeclampsia fetal growth restriction ) , improve deep placentation physiology : invasion transformation spiral artery trophoblast . General Goals : proposal investigator aim 1 . Assess effectiveness maternal supplementation Docosahexaenoic acid ( DHA ) early pregnancy reduce incidence deep placentation disorder : preterm birth , preterm labor , preterm premature rupture membrane , preeclampsia fetal growth restriction . 2 . Study ability DHA supplementation , early pregnancy , enhance invasion transformation spiral artery trophoblast , deep placentation indicator . Methodology : investigator conduct randomize , placebo control , double blind , clinical trial maternal supplementation DHA ( Docosahexaenoic acid ) prevent deep placentation disorder . Women recruit 16 week pregnancy 5 ambulatory center , 2.400 pregnant woman assign 600 mg DHA per day placebo . A composite outcome primary outcome study . The component composite outcome : preterm birth &lt; 34+0 week gestation ; early preeclampsia ( &lt; 34+0 week ) severe fetal growth restriction ( low 2 percentile &lt; 34+0 week ) . Each outcomes composite outcome clinically relevant maternal fetal outcomes evaluate secondary outcome study . Clinical sample obtain pregnant woman group , include : plasma , trophoblast , placental bed myometrium , study change deep placentation defective placentation marker . Trophoblast cell line use study effect DHA trophoblast function vitro . Expected outcome : In randomized clinical trial , 50 % reduction incidence composite outcome DHA group ( 4 % placebo vs. 2 % DHA ) expect . Investigators expect decrease defective deep placentation ( placental bed biopsy ) defective placentation marker DHA supplement woman . Investigators expect also demonstrate DHA enhances trophoblast migration invasion vitro decrease production inflammatory cytokine anti-vasculogenic mediator . Relevance : finding positive , DHA supplementation , early pregnancy , become safe effective strategy primary prevention highly relevant pregnancy disease , preterm birth , preeclampsia fetal growth restriction .</detailed_description>
	<mesh_term>Pre-Eclampsia</mesh_term>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Stillbirth</mesh_term>
	<mesh_term>Fetal Growth Retardation</mesh_term>
	<criteria>Women 18 year old old time consent Capability subject comprehend comply study requirement Live embryo fetus ( document positive fetal heart rate prior randomisation ) Gestational age 16+0 week pregnancy Planning deliver Hospital Dr. Sótero del Río , Hospital Padre Hurtado , Hospital Clínico Universidad Católica de Chile . Preexisting diabetes mellitus . Uterine anatomic malformation ( bicornuate , septate uterus ) . Already take prenatal supplement DHA . Bleeding disorder DHA contraindicate . Anticoagulant therapy . Documented history drug alcohol abuse . Embryo Fetus know mayor abnormality . Unable give write informed consent . In judgment investigator , unwilling unable comply study protocol . Currently participate another fatty acid trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>docosahexaenoic acid</keyword>
	<keyword>premature birth</keyword>
	<keyword>placentation disorder</keyword>
	<keyword>preeclampsia</keyword>
	<keyword>fetal growth</keyword>
</DOC>